Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Harvard Business School
Cantor Fitzgerald
Dow
Baxter
Farmers Insurance
Cipla
Colorcon

Generated: November 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,452,860

« Back to Dashboard

Summary for Patent: 7,452,860
Title:Zinc-free and low-zinc insulin preparations having improved stability
Abstract:The invention relates to a formulation comprising a polypeptide selected from at least one of insulin, an insulin metabolite, an insulin analog, and an insulin derivative; at least one surfactant; optionally at least one preservative; and optionally at least one of an isotonicizing agent, a buffer or an excipient, wherein the formulation is free from or low in zinc. The invention also relates to the production of such insulin preparations and their use as pharmaceutical formulations.
Inventor(s): Boderke; Peter (Frankfurt am Main, DE)
Assignee: Sanofi-Aventis Deutschland GmbH (Frankfurt am Main, DE)
Application Number:11/683,747
Patent Claim Types:
see list of patent claims
Formulation;

Drugs Protected by US Patent 7,452,860

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sanofi Aventis Us APIDRA insulin glulisine recombinant INJECTABLE;IV (INFUSION), SUBCUTANEOUS 021629-001 Apr 16, 2004 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Sanofi Aventis Us APIDRA insulin glulisine recombinant INJECTABLE;IV (INFUSION), SUBCUTANEOUS 021629-002 Dec 20, 2005 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Sanofi Aventis Us APIDRA SOLOSTAR insulin glulisine recombinant INJECTABLE;SUBCUTANEOUS 021629-003 Feb 24, 2009 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,452,860

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany101 14 178Mar 23, 2001

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
McKesson
Johnson and Johnson
Queensland Health
Julphar
Deloitte
Boehringer Ingelheim
Cipla
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.